Home › Burkitt Lymphoma › New Hampshire
Burkitt Lymphoma clinical trials in New Hampshire
4 studies for Burkitt Lymphoma are looking for participants at sites in New Hampshire.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.